Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib

Clin Imaging. 2018 Mar-Apr:48:44-47. doi: 10.1016/j.clinimag.2017.09.014. Epub 2017 Sep 28.

Abstract

Objective: To compare performance of RECIST1.1 and Choi criteria in assessment of patients with metastatic triple-negative breast cancer treated with cabozantinib.

Methods: Thirty patients with metastatic triple-negative breast cancer enrolled in phase 2 clinical trial received cabozantinib. Clinical benefit rates assessed by prospectively determined RECIST1.1 and retrospectively assessed Choi criteria were compared.

Results: Decreased tumor density (≥15%) at first follow-up was seen in 22/30(73%) patients. CBR was 40% (95%CI:23-59%) by RECIST1.1, and 73% (95%CI:54-88%) by Choi (NPV=100%, 95%CI:63-100%; PPV=55%, 95%CI:32-76%).

Conclusions: Morphologic changes are seen in the majority of patients treated with cabozantinib, making Choi criteria valuable in response assessment.

Keywords: Breast cancer; Cabozantinib; Choi; RECIST; Tumor response criteria.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Anilides / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Outcome Assessment, Health Care / methods*
  • Pyridines / therapeutic use*
  • Retrospective Studies
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Anilides
  • Antineoplastic Agents
  • Pyridines
  • cabozantinib